News

Ophthalmology Advisor5h
CDC Now Recommends RSV Vaccine for Some Adults 50 Plus
HealthDay News — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update from the U.S. Centers for Disease Control and Prevention ...
CDC now recommends RSV vaccine for some adults 50+
Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...
CBS News25d
RFK Jr. taps allies and COVID vaccine critics among picks for CDC advisory panel. Here's who's on the list. - CBS News
Former CDC official Jeffrey Klausner, a professor at the USC Keck School of Medicine, said he was among those approached for suggestions early this year. He said none of his suggestions were among ...
Benzinga.com25d
FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up - Benzinga
The CDC currently recommends RSV vaccines for adults 75 and older, plus those 60-74 at increased risk. The final CDC recommendation remains pending for the expanded age group before availability.
Pharmaceutical Technology25d
Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults
The CDC currently recommends the vaccine for adults aged 75 and older, as well as for adults aged 60 to 74 who are at increased risk of infection. In April, the CDC’s ACIP recommended the use of ...
The Lancet26d
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised ... - The Lancet
Nirsevimab offers consistent and sustained protection against hospitalisation due to RSV-associated lower respiratory tract infection for at least 6 months. This finding provides global health systems ...
Nasdaq28d
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
Merck plans to launch Enflonsia in the United States ahead of the upcoming 2025-26 RSV season and expects ordering for the shots to start next month. Per a Reuters article, Merck will price the ...
BioSpace28d
Merck Wins FDA Nod for RSV Antibody, Tees Up Challenge to Sanofi, AstraZeneca - BioSpace
The FDA approved the use of Merck ’s anti-respiratory syncytial virus antibody clesrovimab in infants on Monday. Merck will market the therapy under the brand name Enflonsia. The approval covers the ...
Frontiers28d
Sub-neutralizing levels of antibodies against RSV F protein enhance RSV infection via Fc-FcγR interactions - Frontiers
Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections in infants, and antibody-dependent enhancement (ADE) presents a significant challenge in vaccine and ...
STAT29d
We're reading about FDA and gene therapy, a kidney disease battle | STAT
Sanofi is speeding shipments of its RSV antibody Beyfortus to get ahead of what it believes will be strong demand in the 2025–2026 season ...
STAT29d
Merck’s RSV preventive antibody for infants is approved by FDA
The simplicity of the new monoclonal Enflonsia could give it an advantage over AstraZeneca’s Beyfortus Enflonsia, a monoclonal antibody for RSV, is approved for use in children under 12 months ...